Switch theme
Sign up to access all valuation multiples
Paxman AB is a Sweden based company engaged in the development of PAXMAN Scalp Cooling System that is used to minimize hair loss in connection with chemotherapy treatment. The company offers a stand-alone, mobile electric cooling unit, which is a liquid-based cooling system that cools down the patient's scalp through the silicone hat. Geographically the company markets its product to Great Britain, Scandinavian countries, the Netherlands, Belgium, and Australia.
2016
105
LTM Revenue $30.9M
LTM EBITDA $6.3M
$149M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Paxman has a last 12-month revenue (LTM) of $30.9M and a last 12-month EBITDA of $6.3M.
In the most recent fiscal year, Paxman achieved revenue of $26.1M and an EBITDA of $6.1M.
Paxman expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Paxman valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.9M | XXX | $26.1M | XXX | XXX | XXX |
| Gross Profit | $20.2M | XXX | $18.1M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $6.3M | XXX | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $4.4M | XXX | $3.5M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $4.0M | XXX | $4.1M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Paxman's stock price is SEK 76 (or $8).
Paxman has current market cap of SEK 1.6B (or $164M), and EV of SEK 1.4B (or $149M).
See Paxman trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $149M | $164M | XXX | XXX | XXX | XXX | $0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Paxman has market cap of $164M and EV of $149M.
Paxman's trades at 5.7x EV/Revenue multiple, and 24.5x EV/EBITDA.
Equity research analysts estimate Paxman's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paxman has a P/E ratio of 40.9x.
See valuation multiples for Paxman and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $164M | XXX | $164M | XXX | XXX | XXX |
| EV (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 23.7x | XXX | 24.5x | XXX | XXX | XXX |
| EV/EBIT | 33.9x | XXX | 43.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.9x | XXX | 39.4x | XXX | XXX | XXX |
| EV/FCF | 228.4x | XXX | 93.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPaxman's last 12 month revenue growth is 49%
Paxman's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Paxman's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Paxman's rule of X is 142% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Paxman and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 90% | XXX | 57% | XXX | XXX | XXX |
| Rule of 40 | 64% | XXX | 72% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 142% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paxman acquired XXX companies to date.
Last acquisition by Paxman was XXXXXXXX, XXXXX XXXXX XXXXXX . Paxman acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Paxman founded? | Paxman was founded in 2016. |
| Where is Paxman headquartered? | Paxman is headquartered in Sweden. |
| How many employees does Paxman have? | As of today, Paxman has 105 employees. |
| Is Paxman publicy listed? | Yes, Paxman is a public company listed on STO. |
| What is the stock symbol of Paxman? | Paxman trades under PAX ticker. |
| When did Paxman go public? | Paxman went public in 2017. |
| Who are competitors of Paxman? | Similar companies to Paxman include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Paxman? | Paxman's current market cap is $164M |
| What is the current revenue of Paxman? | Paxman's last 12 months revenue is $30.9M. |
| What is the current revenue growth of Paxman? | Paxman revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Paxman? | Current revenue multiple of Paxman is 4.8x. |
| Is Paxman profitable? | Yes, Paxman is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Paxman? | Paxman's last 12 months EBITDA is $6.3M. |
| What is Paxman's EBITDA margin? | Paxman's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Paxman? | Current EBITDA multiple of Paxman is 23.7x. |
| What is the current FCF of Paxman? | Paxman's last 12 months FCF is $0.7M. |
| What is Paxman's FCF margin? | Paxman's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Paxman? | Current FCF multiple of Paxman is 228.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
